Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Pulmonary/Respiratory Diseases | Family Medicine
Disease Category: Non-Small Cell Lung Cancer
Location: United States, NJ
Clinical Trial Details
Research Study Summary
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
This research is being done because even with the most
aggressive after-surgery treatment with chemotherapy, many people
still have the lung cancer recur (come back).
The purpose of this study is to determine if adding the new drug
bevacizumab to chemotherapy improves the chance for cure for
patients who have had surgery for the removal of the lung cancer.
We will compare the effects (good and bad) of adding bevacizumab to
chemotherapy with standard chemotherapy alone on you and your lung
cancer to see which is better at preventing the cancer from coming
- Diagnosis of stage IB-IIIA (T2-3 N0, T1-3 N1, T1-3 N2)
non-small cell lung cancer (NSCLC)
- Patients with stage IB disease must have tumors measuring >
- Must have undergone complete resection of NSCLC within the past
- Accepted types of resection include any of the following:
- Sleeve lobectomy
- No resection by segmentectomy or wedge resection
To Learn more
Both Male and Female
Date Last Changed:
July 25, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.